Ars Technica: Vaccine trial finds a glitch with children in one age range. https://arstechnica.com/science/2021/12/vaccine-trial-finds-a-glitch-with-children-in-one-age-range/
Why the news alarming with big figures. People around here where I live are still around. Diabetic (Mexicans are diabetogenics) neighbors haven't died. Some claim already catched covid, no deaths. We, me and family, never use facemasks as I already said. We've catched flu symptoms, mild symptoms I'd say, then cured. Why the big numbers, why. Are the facemasks not working? I see most people wearing them. People on Facebook, social media, etc accusing those who don't waer a mask, guilty. Yet I haven't seen a single headline on the news, not a single sentence, stating maskless people are the responsible ones of this Plandemic.
to many experts involved that change their advice on the whims of the media for popularity ! what i dont like is the government making laws forcing employers to fire people who dont get the vaccine shots and discharging solders for not getting them. what next shooting them! these people are not going Anyware they will still be walking around amongst us but now we will have to support them because they got fired. im almost 80 i have had all my shots even the flu shot for this year none of these shots will prevent me from getting any virus but it is supposed to minimize the effect it will have on me if i do get sick . i wear a mask in public when im out and about its not a problem .
Rapid progression of lymphoma after inoculation with Pfizer On this occasion, I share with you a case report, written by Serge Goldman and colleagues, and published in Frontiers Medicine magazine on November 25. The case report, titled “Rapid Progression of Angioimmunoblastic T Lymphoma Following Booster BNT162b2 mRNA Vaccine: A Case Study” (https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8656165/), focuses on a 66-year-old man with no relevant medical history of any type of cancer. First of all, it is necessary to present six concepts for those who are not familiar with the subject. Those who are, can skip this section and go directly to the paragraph that begins with "Several things": 1. Angioimmunoblastic T lymphoma (LTAI, or AITL): A type of peripheral T-cell lymphoma. It is rare (it represents less than 5% of all lymphomas and 20% of T lymphomas). It is often aggressive and affects older people more. 2. Cervical lymphadenopathy: Inflammatory reaction that is triggered by a local stimulus and that corresponds to the lymphatic “drainage” of anatomical points of the head, neck and sometimes upper extremities. 3. Positron Emission Tomography with 18F-fluorodeoxyglucose (PET-FDG): whole-body imaging technique that evaluates the carbohydrate metabolism of cells and thus allows differentiation of malignant tumors from benign tumors. 4. Hypermetabolic cells: it occurs frequently in cancer cells, where their cellular metabolic requirements and activities increase. These cells are usually resistant to chemotherapy. 5. Total tumor glycolysis index (GTT): Value that allows predicting the risk of recurrence and the prognosis of cancers. The higher, the worse the prognosis. 6. RHOA G17V: Common mutation in tissues with LTAI. This mutation, which changes a glycine for a valine in the gene that codes for the RhoA protein that binds to the nucleotide guanine, occurs in 68% of cases of LTAI. Several things caught my attention about the study: 1) The corresponding author is the patient referred to in the case report. 2) They are very careful to state clearly that the patient continues to consider inoculations to be “very efficient products with a favorable benefit-risk ratio” and that what the corresponding patient / author hopes is that their report could “encourage research that clarifies the possible impact of anti-SARS-CoV-2 mRNA vaccination on the course of LTAI ”, 3) in spite of the above, they present their case in a solid way with references from experimental and clinical studies, from which it follows a) the mechanism by which mRNA inoculations can induce lymphomas, and b) that current pharmacovigilance systems are not ready to detect these events as associated with inoculations, and 4) although they do not discuss it, they clearly indicate that there was no increase in SARS-CoV-2 anti-Spike antibody levels after (neither immediately nor 21 days after) receiving the boost (in other words, there was no such "increase" in levels antibodies that both certain authorities and most of the means indicate that the third dose is achieved as a way - wrong and misunderstood about the immune functioning - of being protected against SARS-CoV-2). Now, the summary of the case reported by Goldman and collaborators: The patient had a history of hypertension, hypercholesterolemia (high levels of cholesterol in the blood) and type 2 diabetes. On September 1, 2021, he complained of a flu-like clinical picture in which cervical lymphadenopathy was detected. He had received two doses of the Pfizer / BioNTech inoculation 5 and 6 months ago, respectively. An 18F-FDG PET CT scan was performed and it was found that he had multiple lymphadenopathy above and below the diaphragm, as well as several hypermetabolic lesions that did not belong to the lymph nodes, but were outside of them. The presumptive diagnosis was grade 4 lymphoma and the diagnosis of angioimmunoblastic T-cell lymphoma was confirmed with a biopsy. 14 days after the CT scan was performed, the patient received a Pfizer / BioNTech booster while he was “in preparation for the first chemotherapy cycle ”and a couple of days after the reinforcement, a marked increase in the size of the cervical lymph nodes was observed, for which a second 18F-FDG PET scan was performed. What was obvious was the increase in the number, size and metabolic activity of cancerous tumors in lymph nodes that had already been detected and their presence at other sites. You can see how the image changes in figure 1 of the case report. Furthermore, the total tumor glycolysis index (GTT) had increased by 5.3 times compared to the first test. The patient was started with treatment according to recent protocols. It should be noted that SARS-CoV-2 anti-Spike antibody levels did not change immediately or 21 days after receiving the boost. The authors argue that while it was known that mRNA inoculations could cause inflammation of the lymph nodes near the injection site, and that this was not malignant, studies on hypermetabolic lymphadenopathies (pathologies that are not always benign) after inoculation against SARS-CoV-2 (mainly from Pfizer / BioNTech or Moderna, but also with Astrazeneca). For example, a study of 728 patients who received the Pfizer / BioNTech inoculation showed that 36% and 54% of people had hypermetabolic lymphadenopathy after the 1st and 2nd doses, respectively, showing that the second dose has more impact on lymph nodes. 5% of the patients developed malignant lesions and 15% were inconclusive. The authors note their surprise that none of the studies considered the possibility that mRNA inoculations may have played a role in the development of these malignancies. In this sense, this is the first case report that suggests that the administration of these products to inoculate against SARS-CoV-2 can induce the rapid progression of lymphoma, at a rate that is not expected in the natural course of the disease. illness. Since mRNA inoculation is known to induce growth and hypermetabolic status of lymph nodes near the injection site, the authors consider it reasonable to propose that inoculation was responsible for the observed pathological changes. They also indicate that malignant TFH cells - characteristic of AITL lymphoma, would be particularly sensitive to these mRNA inoculations when the cells have a mutation known as RHOA G17V, which facilitates the proliferation and activity of various cascades that increase the rate of cancer. According to the authors, their report raises the question of what to do with patients like him, who should no longer use these inoculations. The authors are very cautious in stating that the findings of this case should not be extrapolated to other patients with LTAI or other cases of peripheral lymphoma, and that prospective studies involving post-inoculation PET-CT computed tomography in patients with LTAI are needed ( I remind you that the patient in the case did not have LTAI prior to inoculation). Predictably, they indicate that "regardless of the results of these studies, it should not affect the generally favorable benefit-risk ratio of these much-needed vaccines." If we remove the hyperbole (which should not exist in a scientific writing) and we are left with "the veins and the muscle" of his report, the important thing is: 1) the appearance of LTAI six months after the first inoculation in a patient previously without indication of this pathology; 2) the very rapid progression, in just 8 days after receiving the third dose, of cancer; 3) the plausible and biologically coherent mechanism linking mRNA inoculation with cell malignancy. By no means does this case report mean that everyone who receives these inoculations will have this type of event. There are risk factors, genetic predisposition, predisposition by age, immune status, etc. But as they themselves admit, previous studies did not even consider the possibility of a causal relationship with the malignant hypermetabolic lymphadenopathies that were observed. Perhaps these kinds of reports will help other internists and oncologists to ask the right questions again. Your patients need you with a clear and neutral head. I hope this information is useful to you and I wish you have a nice day, Karina AW https://t.me/akashacomunidad/899
No, now I see with much more clarity this Plandemic. My questions are reasonable yet they bother you Are you jealous or you just hate me for charismatic?
U.S. News & World Report: Texas' Harris County Records Its First Death Linked to Omicron Variant. https://www.usnews.com/news/us/arti...-believed-related-to-omicron-variant-abc-news
Let's brace ourselves.... https://www.defenseone.com/technolo...ctive-against-all-covid-sars-variants/360089/ US Army Creates Single Vaccine Effective Against All COVID & SARS Variants, Researchers Say Within weeks, Walter Reed researchers expect to announce that human trials show success against Omicron—and even future strains. Within weeks, scientists at the Walter Reed Army Institute of Research expect to announce that they have developed a vaccine that is effective against COVID-19 and all its variants, even Omicron, as well as from previous SARS-origin viruses that have killed millions of people worldwide. The achievement is the result of almost two years of work on the virus. The Army lab received its first DNA sequencing of the COVID-19 virus in early 2020. Very early on, Walter Reed’s infectious diseases branch decided to focus on making a vaccine that would work against not just the existing strain but all of its potential variants as well. Walter Reed’s Spike Ferritin Nanoparticle COVID-19 vaccine, or SpFN, completed animal trials earlier this year with positive results. Phase 1 of human trials, which tested the vaccine against Omicron and the other variants, wrapped up this month, again with positive results that are undergoing final review, Dr. Kayvon Modjarrad, director of Walter Reed’s infectious diseases branch, said in an exclusive interview with Defense One. Unlike existing vaccines, Walter Reed’s SpFN uses a soccer ball-shaped protein with 24 faces for its vaccine, which allows scientists to attach the spikes of multiple coronavirus strains on different faces of the protein. The vaccine’s human trials took longer than expected, he said, because the lab needed to test the vaccine on subjects who had neither been vaccinated nor previously infected with COVID. Increasing vaccination rates and the rapid spread of the Delta and Omicron variants made that difficult. “With Omicron, there's no way really to escape this virus. You're not going to be able to avoid it. So I think pretty soon either the whole world will be vaccinated or have been infected,” Modjarrad said. The next step is seeing how the new pan-coronavirus vaccine interacts with people who were previously vaccinated or previously sick. Walter Reed is working with a yet-to-be-named industry partner for that wider rollout. “We need to evaluate it in the real-world setting and try to understand how does the vaccine perform in much larger numbers of individuals who have already been vaccinated with something else initially…or already been sick,” Modjarrad said, adding that the new vaccine will still need to undergo phase 2 and phase 3 trials. He said nearly all of Walter Reed’s 2,500 staff have had some role in the vaccine’s nearly-two-year development. “We decided to take a look at the long game rather than just only focusing on the original emergence of SARS, and instead understand that viruses mutate, there will be variants that emerge, future viruses that may emerge in terms of new species. Our platform and approach will equip people to be prepared for that.”
I had a look at it: https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01639-9 TBH I am not convinced and can't share their enthusiasm. And most of it like “We decided to take a look at the long game rather than just only focusing on the original emergence of SARS, and instead understand that viruses mutate, there will be variants that emerge, future viruses that may emerge in terms of new species. Our platform and approach will equip people to be prepared for that.” is nothing new....the mRNA tech can do that already. This approach is based on cross-reaction. They choose epitopes which are in common at multiple coronaviruses. There is a principle! When you try to catch as many variants / kinds of corona viruses at once you lose targets to attack. So the vaccine can fight more of variants, but less specific and therefore less efficient. On the other hand we see waning effectiveness of the vaccines sooner as expected AND we see that vaccines are not sterilizing and we have immune escapes within variants already... So far no vaccine approach has really convinced...I would rather focus on drugs which can disrupt a generic process at viral replication and on monoclonal and polyclonal antibodies as passive immunity.
You would, since this is what you are professionally involved in... Like what solution to your problem do you get if you ask a surgeon - but a surgery... Let's see this play out...
Yes. But I also relate to what we know for influenza vaccines. My argument is based on the following logic. To have best chances for a successful vaccine those vaccines need to mimic a natural infection as close as they can. But of course without the negative issues. We have a respiratory tract related virus and airborne transmission. And we have a virus which does mutate. And we know viruses infect a cell, do replicate there and do present the antigens on their surface. This attracts cytotoxic t cells which kill the infected cell! This is called cellular immunity. Most of vaccine types do NOT stimulate cellular immunity. Why? Simple....the vaccines do not infect cells, therefore no such training. And: The vaccines are injected, the virus though, does not enter this way. Hence another way of 'infection'. This results in less IgA than natural infection. OK, we have now mRNA which transfect the cells. So we can expect cellular immunity. (This I guess is responsible for the fact that mRNA vaccines still can protect us from severe progresses). So we need an oral vaccine or a nasal vaccine that can transfect a cell. This sounds more of a success to me.
Deseret News: This omicron variant symptom happens at night. https://www.deseret.com/coronavirus...n-variant-symptom-night-sweats-sweating-covid
Yet, the emergence of Omicron has thrown a spanner in the works. According to the latest data, just one month after your second Pfizer or AstraZeneca jab, the ability of antibodies to neutralise Omicron is 30 times lower than if you were infected with the Delta variant – reinforcing the message that double-vaccination is no guarantee against infection.
Ivermactin with combination of fluconazole one stop solution Be sure not to take phenarmine maleate if this so called omicron detected : result into direct death. Any bacteria even any fungul attack enters human body & dies just before it splits itself into many many structured speces .
How Bad is My Batch Batch codes and associated deaths, disabilities and illnesses for Covid 19 Vaccines http://howbad.info/